164 related articles for article (PubMed ID: 35345864)
1. Risk factors associated with metastatic site failure in patients with high-risk neuroblastoma.
Lucas JT; Wakefield DV; Doubrovin M; Li Y; Santiago T; Federico SM; Merchant TE; Davidoff AM; Krasin MJ; Shulkin BL; Santana VM; Lee Furman W
Clin Transl Radiat Oncol; 2022 May; 34():42-50. PubMed ID: 35345864
[TBL] [Abstract][Full Text] [Related]
2. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.
Yanik GA; Parisi MT; Naranjo A; Nadel H; Gelfand MJ; Park JR; Ladenstein RL; Poetschger U; Boubaker A; Valteau-Couanet D; Lambert B; Castellani MR; Bar-Sever Z; Oudoux A; Kaminska A; Kreissman SG; Shulkin BL; Matthay KK
J Nucl Med; 2018 Mar; 59(3):502-508. PubMed ID: 28887399
[TBL] [Abstract][Full Text] [Related]
3. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
4. The Association between Tumour Markers and Meta-iodobenzylguanidine Scans in South African Children with High-risk Neuroblastoma.
Van Heerden J; Kruger M; Esterhuizen TM; Hendricks M; Du Plessis J; Engelbrecht G; Janse van Vuuren M; van Emmenes B; Uys R; Burger C; Nyakale N; More S; Brink A
Clin Oncol (R Coll Radiol); 2021 Aug; 33(8):517-526. PubMed ID: 33781675
[TBL] [Abstract][Full Text] [Related]
5.
Giardino S; Piccardo A; Conte M; Puntoni M; Bertelli E; Sorrentino S; Montera M; Risso M; Caviglia I; Altrinetti V; Lanino E; Faraci M; Garaventa A
Pediatr Blood Cancer; 2021 Feb; 68(2):e28775. PubMed ID: 33099289
[TBL] [Abstract][Full Text] [Related]
6. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.
Ladenstein R; Lambert B; Pötschger U; Castellani MR; Lewington V; Bar-Sever Z; Oudoux A; Śliwińska A; Taborska K; Biassoni L; Yanik GA; Naranjo A; Parisi MT; Shulkin BL; Nadel H; Gelfand MJ; Matthay KK; Park JR; Kreissman SG; Valteau-Couanet D; Boubaker A
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):292-305. PubMed ID: 28940046
[TBL] [Abstract][Full Text] [Related]
7. Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma.
Mazloom A; Louis CU; Nuchtern J; Kim E; Russell H; Allen-Rhoades W; Krance R; Paulino AC
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):858-62. PubMed ID: 25245583
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.
Morgenstern DA; Pötschger U; Moreno L; Papadakis V; Owens C; Ash S; Pasqualini C; Luksch R; Garaventa A; Canete A; Elliot M; Wieczorek A; Laureys G; Kogner P; Malis J; Ruud E; Beck-Popovic M; Schleiermacher G; Valteau-Couanet D; Ladenstein R
Pediatr Blood Cancer; 2018 Nov; 65(11):e27363. PubMed ID: 30015396
[TBL] [Abstract][Full Text] [Related]
9. Residual meta-iodobenzyl guanidine (MIBG) positivity following therapy for metastatic neuroblastoma: Patient characteristics, imaging, and outcome.
Usmani N; Deyell RJ; Portwine C; Rafael MS; Moorehead PC; Shammas A; Vali R; Farfan M; Vanniyasingam T; Morgenstern DA; Irwin MS
Pediatr Blood Cancer; 2021 Dec; 68(12):e29289. PubMed ID: 34411405
[TBL] [Abstract][Full Text] [Related]
10. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.
Yanik GA; Parisi MT; Shulkin BL; Naranjo A; Kreissman SG; London WB; Villablanca JG; Maris JM; Park JR; Cohn SL; McGrady P; Matthay KK
J Nucl Med; 2013 Apr; 54(4):541-8. PubMed ID: 23440556
[TBL] [Abstract][Full Text] [Related]
11. MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis.
Bleeker G; van Eck-Smit BL; Zwinderman KH; Versteeg R; van Noesel MM; Kam BL; Kaspers GJ; van Schie A; Kreissman SG; Yanik G; Hero B; Schmidt M; Laureys G; Lambert B; Øra I; Schulte JH; Caron HN; Tytgat GA
Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):222-30. PubMed ID: 25267348
[TBL] [Abstract][Full Text] [Related]
12. MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
DuBois SG; Mody R; Naranjo A; Van Ryn C; Russ D; Oldridge D; Kreissman S; Baker DL; Parisi M; Shulkin BL; Bai H; Diskin SJ; Batra V; Maris JM; Park JR; Matthay KK; Yanik G
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28383813
[TBL] [Abstract][Full Text] [Related]
13. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.
Decarolis B; Schneider C; Hero B; Simon T; Volland R; Roels F; Dietlein M; Berthold F; Schmidt M
J Clin Oncol; 2013 Mar; 31(7):944-51. PubMed ID: 23341514
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
[TBL] [Abstract][Full Text] [Related]
15. Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group.
Streby KA; Parisi MT; Shulkin BL; LaBarre B; Bagatell R; Diller L; Grupp SA; Matthay KK; Voss SD; Yu AL; London WB; Park JR; Yanik GA; Naranjo A
Pediatr Blood Cancer; 2023 Aug; 70(8):e30418. PubMed ID: 37199022
[TBL] [Abstract][Full Text] [Related]
16. Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma.
Polishchuk AL; Li R; Hill-Kayser C; Little A; Hawkins RA; Hamilton J; Lau M; Tran HC; Strahlendorf C; Lemons RS; Weinberg V; Matthay KK; DuBois SG; Marcus KJ; Bagatell R; Haas-Kogan DA
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):839-45. PubMed ID: 24867534
[TBL] [Abstract][Full Text] [Related]
17. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD006301. PubMed ID: 26436598
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.
Ferry I; Kolesnikov-Gauthier H; Oudoux A; Cougnenc O; Schleiermacher G; Michon J; Bogart E; Chastagner P; Proust S; Valteau-Couanet D; Defachelles AS
J Pediatr Hematol Oncol; 2018 Aug; 40(6):426-432. PubMed ID: 29642099
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]